Immune checkpoint modulators | Ligand families | IUPHAR/BPS Guide to IMMUNOPHARMACOLOGY

Home
Ligands
Ligand families
Immune checkpoint modulators

Immune checkpoint modulators C

Overview

This family contains agents that are able to modulate the regulatory mechanisms that control the immune responses of antigen-specific T cells, including those that are approved immunotherapeutics.

Ligands

Ligands of relevance to immunopharmacology are highlighted in blue

abatacept Show summary »« Hide summary More detailed page

belatacept Show summary »« Hide summary More detailed page

lulizumab pegol Show summary »« Hide summary More detailed page

relatlimab Show summary »« Hide summary More detailed page

ipilimumab Show summary »« Hide summary More detailed page

pembrolizumab Show summary »« Hide summary More detailed page

tremelimumab Show summary »« Hide summary More detailed page

tislelizumab Show summary »« Hide summary More detailed page

nivolumab Show summary »« Hide summary More detailed page

moxetumomab pasudotox Show summary »« Hide summary More detailed page

lintuzumab Show summary »« Hide summary More detailed page

vadastuximab talirine Show summary »« Hide summary More detailed page

gemtuzumab ozogamicin Show summary »« Hide summary More detailed page

PD-L1 (programmed cell death 1 ligand 1) {Sp: Human} Show summary »« Hide summary More detailed page

inotuzumab ozogamicin Show summary »« Hide summary More detailed page

cemiplimab Show summary »« Hide summary More detailed page

How to cite this family page

Database page citation:

Immune checkpoint modulators. Accessed on 23/09/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=969.